Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Not yet recruiting 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Conditions

Cushing Syndrome 2Adrenal Hyperplasia, Congenital 2ACTH Syndrome, Ectopic 2

Interventions

pembrolizumab 1270Specimen Handling 870Carboplatin 831Magnetic Resonance Spectroscopy 808Cyclophosphamide 802Cisplatin 728Nivolumab 658Paclitaxel 631Radiotherapy 573Gemcitabine 572Biopsy 529Bevacizumab 475Dexamethasone 440fludarabine 407Docetaxel 378venetoclax 370Oxaliplatin 365Capecitabine 356Fluorouracil 354atezolizumab 341durvalumab 334Rituximab 332Doxorubicin 316Radiosurgery 309Pemetrexed 305Drug Therapy 302Ipilimumab 294Standard of Care 293Etoposide 285Radiation 279

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Metyrapone × 1 year × Clear all
NCT06106295 2025-09-22

Metyrapone for Mild Autonomous Cortisol Secretion (MACS)

Mayo Clinic

Phase 2 Active not recruiting
30 enrolled

ACTH Syndrome, Ectopic, Adrenal Hyperplasia, Congenital, Cushing Syndrome

NCT07138274 2025-08-22

Metyrapone Study for Patients Diagnosed With Mild Autonomous Cortisol Secretion - MACS

Mayo Clinic

Phase 2 Not yet recruiting
90 enrolled

ACTH Syndrome, Ectopic, Adrenal Hyperplasia, Congenital, Cushing Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡